The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: author
Serval ID
serval:BIB_C97D72D13FD1
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles
Journal
Tobacco control
Author(s)
Gilbert A.R., Pinget C., Bovet P., Cornuz J., Shamlaye C., Paccaud F.
ISSN
1468-3318[electronic]
ISSN-L
0964-4563
Publication state
Published
Issued date
2004
Peer-reviewed
Oui
Volume
13
Number
2
Pages
190-5
Language
english
Abstract
OBJECTIVE: To examine the incremental cost effectiveness of the five first line pharmacological smoking cessation therapies in the Seychelles and other developing countries. DESIGN: A Markov chain cohort simulation. SUBJECTS: Two simulated cohorts of smokers: (1) a reference cohort given physician counselling only; (2) a treatment cohort given counselling plus cessation therapy. INTERVENTION: Addition of each of the five pharmacological cessation therapies to physician provided smoking cessation counselling. MAIN OUTCOME MEASURES: Cost per life-year saved (LYS) associated with the five pharmacotherapies. Effectiveness expressed as odds ratios for quitting associated with pharmacotherapies. Costs based on the additional physician time required and retail prices of the medications. RESULTS: Based on prices for currently available generic medications on the global market, the incremental cost per LYS for a 45 year old in the Seychelles was 599 US dollars for gum and 227 dollars for bupropion. Assuming US treatment prices as a conservative estimate, the incremental cost per LYS was significantly higher, though still favourable in comparison to other common medical interventions: 3712 dollars for nicotine gum, 1982 dollars for nicotine patch, 4597 dollars for nicotine spray, 4291 dollars for nicotine inhaler, and 1324 dollars for bupropion. Cost per LYS increased significantly upon application of higher discount rates, which may be used to reflect relatively high opportunity costs for health expenditures in developing countries with highly constrained resources and high overall mortality. CONCLUSION: Pharmacological cessation therapy can be highly cost effective as compared to other common medical interventions in low mortality, middle income countries, particularly if medications can be procured at low prices.
Keywords
Adult, Cohort Studies, Cost-Benefit Analysis, Counseling, Developing Countries, Female, Health Care Costs, Humans, Male, Markov Chains, Middle Aged, Recurrence, Seychelles, Smoking, Smoking Cessation
Pubmed
Web of science
Open Access
Yes
Create date
14/03/2008 10:21
Last modification date
20/08/2019 15:44
Usage data